Medline ® Abstract for Reference 31
of 'Overview of the treatment of acute lymphoblastic leukemia in children and adolescents'
Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol.
Patrick K, Wade R, Goulden N, Rowntree C, Hough R, Moorman AV, Mitchell CD, Vora A
Br J Haematol. 2014 May;165(4):552-5. Epub 2014 Jan 15.
We report the outcome for children and young people with Down syndrome-associated acute lymphoblastic leukaemia (DS-ALL) treated on a contemporary protocol. Compared with non-DS ALL, patients with DS-ALL had an inferior event-free survival (65·6% vs. 87·7% at 5 years; P < 0·00005) and overall survival (70·0% vs. 92·2%; P < 0·00005). Excess treatment-related mortality - was primarily responsible for the worse outcomes for DS-ALL (21·6% at 5 years, vs. 3·3%, P < 0·00005). Minimal residual disease (MRD) risk status was highly discriminant for relapse in DS patients with 0/28 relapses in the MRD low risk group.
Sheffield Children's Hospital, Sheffield, UK.